Genotypes, Phenotypes and Cancer Evolution

Our vision to improve patient outcome through precisely defining when, who and how to treat can only be achieved by innovating in molecular diagnostics and analytic techniques.

This cross-cutting theme will support our research by developing innovative molecular diagnostic techniques, including in blood-based biomarkers and the monitoring of residual disease, to better understand responses to treatment and cancer evolution.

Theme aims

To deliver integrated somatic and germline genetic profiling for patients with cancer
To integrate liquid biopsies with associated genotyping into routine practice for cancer patients to enhance targeted therapy delivery
To focus adjuvant therapy delivery through more exact prognostication of patients with early stage cancer
To use the principles of cancer evolution in biomarker development and therapeutic approaches to prevent drug resistance
To integrate molecular imaging and radiomics with genotyping and phenotyping

Theme lead

Professor Nicholas Turner (pictured above): Academic Consultant Clinical Oncologist at The Institute of Cancr Research, London, expertise in breast cancer therapeutic biomarker development, including circulating tumour DNA